Anju Software

?? Today is #RareDiseaseDay 2025 – a day to shine a light on the 300 Million people living with a rare disease. But awareness alone isn’t enough! With over 90% of rare diseases still lacking an approved treatment, the need for faster diagnosis, smarter trials, and better access to treatments has never been greater. In the world of rare disease research, progress depends on champions – and that’s where Key Opinion Leaders (KOLs) come in. These experts bridge the gap between science, industry, and patient communities, accelerating breakthroughs where they’re needed most. ?? How are rare disease teams leveraging KOLs strategically to drive real impact? Check it out in our latest article! ?? https://lnkd.in/g7QC69Mf #RareDisease #KOLs #LifeSciences #CollaborationMatters #TAScan?#LightUpForRare

?? ????????: ?????? ???? ?????????????????? ???????? ?????????????? ???????? ?????????????????????? ?? With over 90% of rare diseases lacking approved treatments, KOLs are crucial in accelerating research and driving innovations. From improving early diagnosis to enhancing clinical trial strategies and ensuring market access, their influence is key to transforming patient outcomes. Check out our latest blog to see how KOLs are shaping the future of rare disease drug development. ?? Read more here: https://lnkd.in/g7QC69Mf #RareDiseases #KOLs #DrugDevelopment #Innovation

???????? ?????????????????? ???????? ???? ???????? ???? ???????? ?????????????? ???????? ?????????????????????? ?? Rare diseases present unique challenges in diagnosis and treatment, with over 90% still lacking an approved treatment. However, the pace of innovation is accelerating, with a record number of rare disease drug approvals in 2024. Key Opinion Leaders (KOLs) play a critical role throughout the drug development process—from early disease characterization to regulatory navigation and market access. Their expertise is essential in improving early diagnosis, driving clinical innovation, and ensuring successful treatment adoption. In our latest blog, we dive deep into how KOLs help bridge the gap between scientific discovery and real-world impact, and explore how leveraging data-driven approaches can streamline KOL identification and engagement. ?? ???????? ???????? ???? ?????? ???????? ?????? ???????????????????????? ???????? ?????????????? ???????? ??????????????????????: https://lnkd.in/g7QC69Mf #RareDiseases #KOLs #DrugDevelopment #MedicalAffairs #Healthcare #PatientCentric #LifeSciences #funwithTAScan

??Elke Ydens and Gudrun Skiba will be attending ACDM25 in Prague from March 2-4!?? This event for clinical data management professionals features world-class speakers, cutting-edge workshops, and panel discussions designed to expand your knowledge and foster connections. ????????’?? ???????? ???????? ??????????’ ????????????????????????: ??? ????????????, ?????????? ??, ???????? ?? ??:???? ???? ?? Leveraging AI for Streamlined Protocol Design in Subpopulation-Specific Clinical Trials Connect with Elke and Gudrun, and discover how Anju’s innovative solutions are advancing clinical data management. Let’s shape the future of clinical research together! #ACDM25 #ClinicalTrials #ClinicalResearch #ClinicalDataManagement #funwithtascan

? Just a few weeks until DIA MASC! ?? ?????????? ????-????, ???????? | ????????????, ???? | ?????????? ?????? Meet Anju’s Tyler Gill, Greg Flett-Davies, and Erick Borg to explore how our Medical Affairs suite can help you navigate evolving regulations, enhance medical communications, and keep pace with industry demands. Stop by ?????????? ?????? to connect with us—we look forward to seeing you there! Learn more: https://bit.ly/anjuevents #MASC25 #MedicalAffairs #ScientificCommunications #medicalinformation #MedicalCommunication #MSL #KOLs #PubstratMAX #IRMSMAX

I’m excited to be speaking at the ACDM Conference about one of the most talked-about topics in our industry—AI in clinical trials. While AI promises to revolutionize trial design, patient recruitment, and site selection, real-world adoption comes with challenges. Join me as I dive into how we can start 'Leveraging AI for Streamlined Protocol Design in Subpopulation-Specific Clinical Trials' See you next week in Prague! #ACDM2025 #ClinicalTrials #AIinClinicalTrials #ArtificialIntelligence #DataDriven

?? Last Chance to Register! ?? Tomorrow, the industry’s top experts will reveal their secrets to clinical trial feasibility success. Are you in? ?? Best in Show Winner at SCOPE 2025 – Anju presents: The Three Little Pigs’ Tale: A Strategic Approach to Clinical Trial Feasibility, featuring Industry experts: Elke Ydens, Barbara Argibay, & Laura Acosta ? Build precise enrollment models to improve trial success ? Optimize site selection for maximum efficiency ? Plan ahead for unforeseen challenges that could delay trials ?? Tomorrow – February 25, 2025 ? 10 AM EST | 4 PM CET | 7 AM PST Spots are almost full – Secure yours now! ?? https://lnkd.in/gCphSPTB

Join Our Team at Anju Software! We currently have two openings in Spain: 1. Senior Software Engineer 2. Junior Software Engineer If you're passionate about advancing life sciences through technology and thrive in a collaborative environment, we'd love to hear from you! To apply, please email your cover letter and resume, specifying the desired position, to [email protected]. For more details, visit our careers page:

?? 80% of clinical trials fail to meet enrollment goals. ?? But award-winning strategies can make the difference. Anju – Best in Show Winner at SCOPE 2025 – is hosting a must-attend webinar to help you overcome trial feasibility challenges: ?? The Three Little Pigs’ Tale: A Strategic Approach to Clinical Trial Feasibility Led by Elke Ydens, Laura Acosta, & Barbara Argibay Gonzalez, this session will show you how to: ?? Build data-driven enrollment models ?? Optimize site selection for better trial efficiency ?? Predict & prevent costly feasibility roadblocks ?? February 25, 2025 | ? 10 AM EST | 4 PM CET | 7 AM PST ? Spots are filling fast! Secure yours today: https://lnkd.in/gCphSPTB

?? Solving Rare Disease Trial Challenges with Smarter Insights ?? With over 300 million people worldwide affected by rare diseases, finding the right patients and investigators is a major hurdle. TA Scan streamlines the process by helping sponsors identify experts, expand investigator networks, and optimize trial strategies with real-time data. ? How TA Scan Helps: ?? Find hard-to-reach patient populations ?? Identify emerging investigators in niche fields ?? Expand networks beyond traditional centers For rare disease trials, innovation isn’t optional—it’s essential. Learn how TA Scan makes a difference. ?? Read more: